Providers

Speakers at Patient-Centered Oncology Care® highlighted injustices in the US health care system, the risk of financial toxicity, and how providers can do a better job to ensure their patients achieve health equity, during a panel discussion.

In the real world, dupilumab has been as effective as the results in clinical trials, and patients are seeing low exacerbation rates, emergency department visits, and hospitalizations, explained Neal Jain, MD, FAAP, FAAAAI.

More biosimilars are hitting the US market, but marketplace dynamics have made it difficult to take advantage of these therapies.

Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.

In individuals with type 2 diabetes with no previous insulin treatment, once-weekly injections of insulin icodec resulted in glucose-lowering efficacy and a safety profile similar to individuals who took once-daily insulin glargine U100.

Pediatric patients who had a referral from their pediatric rheumatologist and continued insurance coverage saw decreased delays when transitioning to an adult rheumatology clinic.

Patients who have oral corticosteroid–dependent asthma are recommended to use dupilumab, which reduces the use of oral steroids, explained Neal Jain, MD, FAAP, FAAAAI, of Arizona Allergy & Immunology Research.

Emerging data is showing that treatment within 6 months of presentation of multiple sclerosis (MS) is ideal, explained Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute.

As cancer care providers, aligning care with each patient's personal goals is a key point to be further discussed at this year's Patient-Centered Oncology Care® 2020 virtual conference.

The high rate of persistence found in the real-world study indicates dupilumab was well tolerated and patients were satisfied with its effectiveness.

We should look forward to a safe, effective vaccine for coronavirus disease 2019 (COVID-19) but not expect it to be the ultimate panacea.

Obesity is common in the general population and research has shown it can increase the risk of multiple sclerosis (MS), as well as increase diagnostic delays, explained Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba.

Nurses often get involved with patients with multiple sclerosis (MS) before their diagnosis and then work to educate them on the disease and its care, said Amy Perrin Ross, APN, MSN, CNRN, MSCN, Neuroscience Program Coordinator at Loyola University Medical Center.

With more multiple sclerosis (MS) treatments becoming available, it is now possible to better personalize approaches, explained speakers during a session at MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.

Even though dupilumab was a late entrant to the market to treat asthma, its efficacy “speaks for itself,” said Neal Jain MD, FAAP, FAAAAI, of Arizona Allergy & Immunology Research, Arcadia Allergy & Asthma, and San Tan Allergy & Asthma.

In recent years, the number of children diagnosed with additional autoimmune diseases accompanying type 1 diabetes (T1D) has increased, according to a study published in Frontiers in Endocrinology.

Telehealth has been around for years in the United States, but it was not until the coronavirus disease 2019 (COVID-19) pandemic that it became so widely used.

Telehealth claim lines increased 4132% nationally from June 2019 to June 2020, rising from 0.16% of medical claim lines in June 2019 to 6.85% in June 2020, according to new data from FAIR Health’s Monthly Telehealth Regional Tracker.

Comorbidities can have an impact on the main disease domains for patients with psoriatic arthritis. For each additional comorbidity a patient has, their disease activity score increases.

Data presented during the European Society for Cardiology 2020 Congress were a follow-up to the presentation of VERTIS CV at the American Diabetes Association Scientific Sessions in June.

There was no statistically significant difference in patient-reported outcomes for short-term integrated palliative care compared with standard care in those with long-term neurological conditions.

Despite progress from disease-modifying antirheumatic drugs, there is still a far greater long-term risk of undergoing total knee and hip arthroplasties in patients with rheumatoid arthritis.

Data to be presented at SLEEP 2020 showed Eisai Inc's lemborexant (DAYVIGO) had statistically significant long-term efficacy and safety compared with placebo on sleep maintenance and onset in patients with insomnia disorder, said Margaret Moline, PhD.

A Boxed Warning on increased risk of leg and foot amputations has been removed from the label of canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor.